PL EN


Preferences help
enabled [disable] Abstract
Number of results
2012 | 12 | 2 | 104-128
Article title

Histologiczne kryteria diagnostyczne oponiaków atypowych (GII WHO) i ich związek z potencjałem proliferacyjnym

Content
Title variants
EN
Histologic features and MIB-1/Ki67 indices in atypical meningiomas (GII WHO)
Languages of publication
PL
Abstracts
EN
Atypical meningiomas are defined according WHO criteria as tumours characterized by: increased mitotic activity or three or more of the following histologic features: increased cellularity, small cells with a high nuclear/cytoplasmic ratio, prominent nucleoli, patternless or sheet like growth, and foci of “spontaneous” or “geographic” necrosis. It means, that those meningiomas which reveal only one or even two from above mentioned features are, according to WHO classification, still consistent with diagnosis of benign (GI WHO) tumours. Histologic slices from 65 atypical meningiomas were investigated and presence of each from those diagnostic histologic criteria which were mentioned above, were taken to account. Additionally, in the same way 59 benign meningiomas, which showed one or two histologic features char-acteristic for atypical type of the tumours, were analysed. In all cases immunohistochemical reaction with MIB-1 antibody was carried out and proliferating indices (PI) were established using image analysis computer system. Correlation between histologic criteria for atypical meningiomas and proliferating indices of the tumours was statistically estimated. We found a significant relationship between PI and mitotic activity, necrosis, small cells changes, patternless growth, nucleolies and number of histologic features that tumors present.
PL
Oponiaki atypowe zostały zdefiniowane w klasyfikacji WHO jako nowotwory charakteryzujące się histologicznie bądź aktywnością mitotyczną o wartości 4-20 mitoz/10 HPF, bądź co najmniej trzema spośród pięciu następujących cech: gęstokomórkowe utkanie, małe komórki z przesuniętym na korzyść jądra współczynnikiem „jądrowo-cytoplazmatycznym”, jądro z wyraźnym jąderkiem, brak struktur cytoarchitektonicznych (ang. patternless or sheet-like growth) i ogniska martwicy. Oznacza to, że guzy ukazujące mikroskopowo jedną, a nawet dwie spośród wymienionych cech należy zaliczyć, mimo tych nieprawidłowości, do grupy oponiaków łagodnych (GI WHO). Celem przeprowadzonych badań było poszukiwanie w grupie pięciu kryteriów diagnostycznych oponiaków atypowych wg WHO takich cech histologicznych, które w największym stopniu korelują z wartością indeksu proliferacyjnego tych nowotworów. Materiał badawczy obejmował 65 oponiaków atypowych oraz 59 oponiaków łagodnych, wykazujących przynajmniej jedną cechę histologiczną charakterystyczną dla oponiaków atypowych, wybranych spośród 240 archiwalnych przypadków z lat 2004-2011. Wszystkie nowotwory zostały ocenione pod względem pięciu histologicznych kryteriów diagnostycznych dla oponiaków atypowych oraz liczby mitoz na dziesięć pól widzenia. We wszystkich badanych guzach wykonano reakcję immunohistochemiczną z przeciwciałem MIB-1. Indeks proliferacyjny (PI) obliczono za pomocą komputerowego analizatora obrazu. Uzyskane wyniki poddano analizie statystycznej. W wyniku przeprowadzonych badań stwierdzono związek PI z ogniskami martwicy, wyraźnymi jąderkami, brakiem układów cytoarchitektonicznych charakterystycznych dla oponiaków GI WHO, obecnością drobnych komórek ze zwiększonym stosunkiem jądrowo-cytoplazmatycznym oraz liczbą cech histologicznych.
Discipline
Year
Volume
12
Issue
2
Pages
104-128
Physical description
References
  • 1. CBTRUS (2010). CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2006. Source: Central Brain Tumor Registry of the United States, Hinsdale, IL. Adres: www.cbtrus.org.
  • 2. CBTRUS (2011). CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2007. Source: Central Brain Tumor Registry of the United States, Hinsdale, IL. Adres: www.cbtrus.org.
  • 3. Durand A., Labrousse F., Jouvet A. i wsp.: WHO grade II and III meningiomas: a study of prognostic factors. J. Neurooncol. 2009; 95: 367-375.
  • 4. Wiemels J., Wrensch M., Claus E.B.: Epidemiology and etiology of meningioma. J. Neurooncol. 2010; 99: 307-314.
  • 5. Burger P.C., Scheithauer B.W.: Tumor of meningothelial cells. W: Rosai J. (red.): Tumors of the Central Nervous System. Armed Forces Institute of Pathology, Washington 1994: 259-286.
  • 6. Kleihues P., Cavenee W.K.: Pathology and Genetics of Tumours of the Central Nervous System. IARC Press, Lyon 2000.
  • 7. Modha A., Gutin P.H.: Diagnosis and treatment of atypical and anaplastic meningiomas: a review. Neurosurgery 2005; 57: 538-550; discussion 538-550.
  • 8. Abramovich C.M., Prayson R.A.: Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas. Arch. Pathol. Lab. Med. 1999; 123: 793-800.
  • 9. Commins D.L., Atkinson R.D., Burnett M.E.: Review of meningioma histopathology. Neurosurg. Focus 2007; 23: E3.
  • 10. Bruna J., Brell M., Ferrer I. i wsp.: Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma. Neuropathology 2007; 27: 114-120.
  • 11. Heinrich B., Hartmann C., Stemmer-Rachamimov A.O. i wsp.: Multiple meningiomas: Investigating the molecular basis of sporadic and familial forms. Int. J. Cancer 2003; 103: 483-488.
  • 12. Lee Y., Liu J., Patel S. i wsp.: Genomic landscape of meningiomas. Brain Pathol. 2010; 20: 751-762.
  • 13. Kim Y.J., Ketter R., Steudel W.I., Feiden W.: Prognostic significance of the mitotic index using the mitosis marker antiphosphohistone H3 in meningiomas. Am. J. Clin. Pathol. 2007; 128: 118-125.
  • 14. Cancès C., Chaix Y., Karsenty C. i wsp.: [Clear cell meningioma: recurrent intraspinal tumor in a child]. Arch. Pediatr. 1998; 5: 758-762.
  • 15. Di Rocco C., Di Rienzo A.: Meningiomas in childhood. Crit. Rev. Neurosurg. 1999; 9: 180-188.
  • 16. Erşahin Y., Ozdamar N., Demirtaş E., Karabiyikoğlu M.: Meningioma of the cavernous sinus in a child. Childs Nerv. Syst. 1999; 15: 8-10.
  • 17. Shah S.H., Soomro I.N., Hussainy A.S., Hassan S.H.: Clinico- morphological pattern of intracranial tumors in children. J. Pak. Med. Assoc. 1999; 49: 63-65.
  • 18. Baumgartner J.E., Sorenson J.M.: Meningioma in the pediatric population. J. Neurooncol. 1996; 29: 223-228.
  • 19. Erdinçler P., Lena G., Sarioğlu A.C. i wsp.: Intracranial meningiomas in children: review of 29 cases. Surg. Neurol. 1998; 49: 136-140; discussion 140-141.
  • 20. Menon G., Nair S., Sudhir J. i wsp.: Childhood and adolescent meningiomas: a report of 38 cases and review of literature. Acta Neurochir. (Wien) 2009; 151: 239-244; discussion 244.
  • 21. Byard R.W., Bourne A.J., Clark B., Hanieh A.: Clinicopathological and radiological features of two cases of intraventricular meningioma in childhood. Pediatr. Neurosci. 1989; 15: 260-264.
  • 22. Mallucci C.L., Parkes S.E., Barber P. i wsp.: Paediatric meningeal tumours. Childs Nerv. Syst. 1996; 12: 582-588; discussion 589.
  • 23. Preston D.L., Ron E., Yonehara S. i wsp.: Tumors of the nervous system and pituitary gland associated with atomic bomb radiation exposure. J. Natl Cancer Inst. 2002; 94: 1555-1563.
  • 24. Ron E., Modan B., Boice J.D. Jr i wsp.: Tumors of the brain and nervous system after radiotherapy in childhood. N. Engl. J. Med. 1988; 319: 1033-1039.
  • 25. Sadetzki S., Flint-Richter P., Ben-Tal T., Nass D.: Radiation- induced meningioma: a descriptive study of 253 cases. J. Neurosurg. 2002; 97: 1078-1082.
  • 26. Longstreth W.T., Phillips L.E., Drangsholt M. i wsp.: Dental X-rays and the risk of intracranial meningioma. Cancer 2004; 100: 1026-1034.
  • 27. Ryan P., Lee M.W., North B., McMichael A.J.: Amalgam fillings, diagnostic dental x-rays and tumours of the brain and meninges. Eur. J. Cancer B Oral Oncol. 1992; 28B: 91-95.
  • 28. Cardis E., Deltour I., Vrijheid M. i wsp.: Brain tumour risk in relation to mobile telephone use: results of the INTERPHONE international case-control study. Int. J. Epidemiol. 2010; 39: 675-694.
  • 29. Frei P., Poulsen A.H., Johansen C. i wsp.: Use of mobile phones and risk of brain tumours: update of Danish cohort study. BMJ 2011; 343: d6387.
  • 30. Johansen C., Boice J. Jr, McLaughlin J., Olsen J.: Cellular telephones and cancer – a nationwide cohort study in Denmark. J. Natl Cancer Inst. 2001; 93: 203-207.
  • 31. Hu J., Little J., Xu T. i wsp.: Risk factors for meningioma in adults: a case-control study in northeast China. Int. J. Cancer 1999; 83: 299-304.
  • 32. Black P., Carroll R., Zhang J.: The molecular biology of hormone and growth factor receptors in meningiomas. Acta Neurochir. Suppl. 1996; 65: 50-53.
  • 33. Omulecka A., Papierz W., Nawrocka-Kunecka A., Lewy- -Trenda I.: Immunohistochemical expression of progesterone and estrogen receptors in meningiomas. Folia Neuropathol. 2006; 44: 111-115.
  • 34. Pravdenkova S., Al-Mefty O., Sawyer J., Husain M.: Progesterone and estrogen receptors: opposing prognostic indicators in meningiomas. J. Neurosurg. 2006; 105: 163-173.
  • 35. Custer B., Longstreth W.T. Jr, Phillips L.E. i wsp.: Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study. BMC Cancer 2006; 6: 152.
  • 36. Custer B.S., Koepsell T.D., Mueller B.A.: The association between breast carcinoma and meningioma in women. Cancer 2002; 94: 1626-1635.
  • 37. Claus E.B., Black P.M., Bondy M.L. i wsp.: Exogenous hormone use and meningioma risk: what do we tell our patients? Cancer 2007; 110: 471-476.
  • 38. Vadivelu S., Sharer L., Schulder M.: Regression of multiple intracranial meningiomas after cessation of long-term progesterone agonist therapy. J. Neurosurg. 2010; 112: 920-924.
  • 39. Blitshteyn S., Crook J.E., Jaeckle K.A.: Is there an association between meningioma and hormone replacement therapy? J. Clin. Oncol. 2008; 26: 279-282.
  • 40. Jhawar B.S., Fuchs C.S., Colditz G.A., Stampfer M.J.: Sex steroid hormone exposures and risk for meningioma. J. Neurosurg. 2003; 99: 848-853.
  • 41. Wigertz A., Lönn S., Mathiesen T. i wsp.: Swedish Interphone Study Group: Risk of brain tumors associated with exposure to exogenous female sex hormones. Am. J. Epidemiol. 2006; 164: 629-636.
  • 42. Lee E., Grutsch J., Persky V. i wsp.: Association of meningioma with reproductive factors. Int. J. Cancer 2006; 119: 1152-1157.
  • 43. Benson V.S., Pirie K., Green J. i wsp.: Million Women Study Collaborators: Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort. Br. J. Cancer 2008; 99: 185-190.
  • 44. Korhonen K., Salminen T., Raitanen J. i wsp.: Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression. J. Neurooncol. 2006; 80: 1-7.
  • 45. Rao G., Giordano S.H., Liu J., McCutcheon I.E.: The association of breast cancer and meningioma in men and women. Neurosurgery 2009; 65: 483-489.
  • 46. Eskandary H., Sabba M., Khajehpour F., Eskandari M.: Incidental findings in brain computed tomography scans of 3000 head trauma patients. Surg. Neurol. 2005; 63: 550-553.
  • 47. Inskip P.D., Mellemkjaer L., Gridley G., Olsen J.H.: Incidence of intracranial tumors following hospitalization for head injuries (Denmark). Cancer Causes Control 1998; 9: 109-116.
  • 48. Mawrin C., Perry A.: Pathological classification and molecular genetics of meningiomas. J. Neurooncol. 2010; 99: 379-391.
  • 49. Perry A., Gutmann D.H., Reifenberger G.: Molecular pathogenesis of meningiomas. J. Neurooncol. 2004; 70: 183-202.
  • 50. Hansson C.M., Buckley P.G., Grigelioniene G. i wsp.: Comprehensive genetic and epigenetic analysis of sporadic meningioma for macro-mutations on 22q and micro-mutations within the NF2 locus. BMC Genomics 2007; 8: 16.
  • 51. Carvalho L.H., Smirnov I., Baia G.S. i wsp.: Molecular signatures define two main classes of meningiomas. Mol. Cancer 2007; 6: 64.
  • 52. Shen Y., Nunes F., Stemmer-Rachamimov A. i wsp.: Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas. BMC Med. Genomics 2009; 2: 42.
  • 53. Antinheimo J., Haapasalo H., Haltia M. i wsp.: Proliferation potential and histological features in neurofibromatosis 2-associated and sporadic meningiomas. J. Neurosurg. 1997; 87: 610-614.
  • 54. Choy W., Kim W., Nagasawa D. i wsp.: The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. Neurosurg. Focus 2011; 30: E6.
  • 55. Dezamis E., Sanson M.: [The molecular genetics of meningiomas and genotypic/phenotypic correlations]. Rev. Neurol. (Paris) 2003; 159: 727-738.
  • 56. Gabeau-Lacet D., Engler D., Gupta S. i wsp.: Genomic profiling of atypical meningiomas associates gain of 1q with poor clinical outcome. J. Neuropathol. Exp. Neurol. 2009; 68: 1155-1165.
  • 57. Pham M.H., Zada G., Mosich G.M. i wsp.: Molecular genetics of meningiomas: a systematic review of the current literature and potential basis for future treatment paradigms. Neurosurg. Focus 2011; 30: E7.
  • 58. Riemenschneider M.J., Perry A., Reifenberger G.: Histological classification and molecular genetics of meningiomas. Lancet Neurol. 2006; 5: 1045-1054.
  • 59. Simon M., Boström J.P., Hartmann C.: Molecular genetics of meningiomas: from basic research to potential clinical applications. Neurosurgery 2007; 60: 787-798; discussion 787-798.
  • 60. Wozniak K., Piaskowski S., Gresner S.M. i wsp.: BCR expression is decreased in meningiomas showing loss of heterozygosity of 22q within a new minimal deletion region. Cancer Genet. Cytogenet. 2008; 183: 14-20.
  • 61. Babu S., Uppin S.G., Uppin M.S. i wsp.: Meningiomas: correlation of Ki67 with histological grade. Neurol. India 2011; 59: 204-207.
  • 62. Takeuchi H., Kubota T., Kabuto M. i wsp.: Prediction of recurrence in histologically benign meningiomas: proliferating cell nuclear antigen and Ki-67 immunohistochemical study. Surg. Neurol. 1997; 48: 501-506.
  • 63. Torp S.H., Lindboe C.F., Granli U.S. i wsp.: Comparative investigation of proliferation markers and their prognostic relevance in human meningiomas. Clin. Neuropathol. 2001; 20: 190-195.
  • 64. Torp S.H., Lindboe C.F., Grønberg B.H. i wsp.: Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas. Clin. Neuropathol. 2005; 24: 170-174.
  • 65. Hall P.A., Coates P.J.: Assessment of cell proliferation in pathology – what next? Histopathology 1995; 26: 105-112.
  • 66. Brown D.C., Gatter K.C.: Monoclonal antibody Ki-67: its use in histopathology. Histopathology 1990; 17: 489-503.
  • 67. Quinn C.M., Wright N.A.: The clinical assessment of proliferation and growth in human tumours: evaluation of methods and applications as prognostic variables. J. Pathol. 1990; 160: 93-102.
  • 68. Abry E., Thomassen I.Ø., Salvesen Ø.O., Torp S.H.: The significance of Ki-67/MIB-1 labeling index in human meningiomas: a literature study. Pathol. Res. Pract. 2010; 206: 810-815.
  • 69. Roser F., Samii M., Ostertag H., Bellinzona M.: The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases. Acta Neurochir. (Wien) 2004; 146: 37-44; discussion 44.
  • 70. Takahashi J.A., Ueba T., Hashimoto N. i wsp.: The combination of mitotic and Ki-67 indices as a useful method for predicting short-term recurrence of meningiomas. Surg. Neurol. 2004; 61: 149-155; discussion 155-156.
  • 71. Vankalakunti M., Vasishta R.K., Das Radotra B., Khosla V.K.: MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas. Neuropathology 2007; 27: 407-412.
  • 72. Kordek R.: Ocena aktywności proliferacyjnej nowotworów pochodzenia glejowego. W: Mossakowski M.J., Liberski P.P. (red.): Guzy układu nerwowego. Ossolineum, Wrocław – Warszawa – Kraków 1997: 41-44.
  • 73. Kros J.M., Hop W.C., Godschalk J.J., Krishnadath K.K.: Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas. Cancer 1996; 78: 1107-1113.
  • 74. Sawhney N., Hall P.A.: Ki-67 structure, function, and new antibodies. J. Pathol. 1992; 168: 161-162.
  • 75. Lanzafame S., Torrisi A., Barbagallo G. i wsp.: Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up. Pathol. Res. Pract. 2000; 196: 483-488.
  • 76. Maes L., Kalala J.P., Cornelissen M., De Ridder L.: PCNA, Ki-67 and hTERT in residual benign meningiomas. In Vivo 2006; 20: 271-275.
  • 77. Striepecke E., Handt S., Weis J. i wsp.: Correlation of histology, cytogenetics and proliferation fraction (Ki-67 and PCNA) quantitated by image analysis in meningiomas. Pathol. Res. Pract. 1996; 192: 816-824.
  • 78. Travali S., Ku D.H., Rizzo M.G. i wsp.: Structure of the human gene for the proliferating cell nuclear antigen. J. Biol. Chem. 1989; 264: 7466-7472.
  • 79. Kordek R., Biernat W., Alwasiak J., Liberski P.P.: Proliferating cell nuclear antigen (PCNA) and Ki-67 immunopositivity in human astrocytic tumours. Acta Neurochir. (Wien) 1996; 138: 509-512; discussion 513.
  • 80. McCormick D., Hall P.A.: The complexities of proliferating cell nuclear antigen. Histopathology 1992; 21: 591-594.
  • 81. Taylor C.R., Shi S.R., Chaiwun B. i wsp.: Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen, and Ki-67 antigen revealed by antigen retrieval techniques. Hum. Pathol. 1994; 25: 263-270.
  • 82. Louis D.N., Edgerton S., Thor A.D., Hedley-Whyte E.T.: Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: a comparative study. Acta Neuropathol. 1991; 81: 675-679.
  • 83. Karamitopoulou E., Perentes E., Diamantis I., Maraziotis T.: Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB 1 monoclonal antibody on archival material. Acta Neuropathol. 1994; 87: 47-54.
  • 84. Khoshyomn S., Maier H., Morimura T. i wsp.: Immunostaining for proliferating cell nuclear antigen: its role in determination of proliferation in routinely processed human brain tumor specimens. Acta Neuropathol. 1993; 86: 582-589.
  • 85. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K. (red.): WHO Classification of Tumours of the Central Nervous System. International Agency for Research on Cancer, Lyon 2007.
  • 86. Yu S.Q., Wang J.S., Ji N. i wsp.: Clinical characteristics and therapeutic strategies of atypical meningioma. Chin. Med. J. (Engl.) 2011; 124: 1094-1096.
  • 87. Sughrue M.E., Kane A.J., Shangari G. i wsp.: The relevance of Simpson Grade I and II resection in modern neurosurgical treatment of World Health Organization Grade I meningiomas. J. Neurosurg. 2010; 113: 1029-1035.
  • 88. Heleniak M.: Zależność czasu przeżycia chorych z glejakiem wielopostaciowym od stopnia resekcji. Praca doktorska. Promotor: Prof. dr hab. n. med. Marek Zawirski. Klinika Neurochirurgii i Onkologii Układu Nerwowego Uniwersytetu Medycznego w Łodzi, Łódź 2011: 34-45.
  • 89. Nakaya K., Chernov M., Kasuya H. i wsp.: Risk factors for regrowth of intracranial meningiomas after gamma knife radiosurgery: importance of the histopathological grade and MIB-1 index. Minim. Invasive Neurosurg. 2009; 52: 216-221.
  • 90. Aghi M.K., Carter B.S., Cosgrove G.R. i wsp.: Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery 2009; 64: 56-60; discussion 60.
  • 91. Adegbite A.B., Khan M.I., Paine K.W., Tan L.K.: The recurrence of intracranial meningiomas after surgical treatment. J. Neurosurg. 1983; 58: 51-56.
  • 92. Abdelzaher E., El-Gendi S.M., Yehya A., Gowil A.G.: Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression. Br. J. Neurosurg. 2011; 25: 707-713.
  • 93. Maiuri F., De Caro M.B., Esposito F. i wsp.: Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors. J. Neurooncol. 2007; 82: 63-68.
  • 94. Ozen O., Demirhan B., Altinörs N.: Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas. Clin. Neuropathol. 2005; 24: 219-224.
  • 95. Tyagi A., Chakrabarty A., Franks A.: MIB1 proliferation index in meningiomas: does it predict recurrence? A clinicopathological study. Br. J. Neurosurg. 2004; 18: 357-361.
  • 96. Abramovich C.M., Prayson R.A.: MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors. Hum. Pathol. 1998; 29: 1420-1427.
  • 97. Yang S.Y., Park C.K., Park S.H. i wsp.: Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J. Neurol. Neurosurg. Psychiatry 2008; 79: 574-580.
  • 98. Nakasu S., Fukami T., Jito J., Nozaki K.: Recurrence and regrowth of benign meningiomas. Brain Tumor Pathol. 2009; 26: 69-72.
  • 99. Nakasu S., Li D.H., Okabe H. i wsp.: Significance of MIB-1 staining indices in meningiomas: comparison of two counting methods. Am. J. Surg. Pathol. 2001; 25: 472-478.
  • 100. Kim Y.J., Ketter R., Henn W. i wsp.: Histopathologic indicators of recurrence in meningiomas: correlation with clinical and genetic parameters. Virchows Arch. 2006; 449: 529-538.
  • 101. Perry A., Stafford S.L., Scheithauer B.W. i wsp.: Meningioma grading: an analysis of histologic parameters. Am. J. Surg. Pathol. 1997; 21: 1455-1465.
  • 102. Schiffer D., Ghimenti C., Fiano V.: Absence of histological signs of tumor progression in recurrences of completely resected meningiomas. J. Neurooncol. 2005; 73: 125-130.
  • 103. Akyildiz E.U., Oz B., Comunoglu N., Aki H.: The relationship between histomorphological characteristics and Ki-67 proliferation index in meningiomas. Bratisl. Lek. Listy 2010; 111: 505-509.
  • 104. Willis J., Smith C., Ironside J.W. i wsp.: The accuracy of meningioma grading: a 10-year retrospective audit. Neuropathol. Appl. Neurobiol. 2005; 31: 141-149.
  • 105. Ho D.M., Hsu C.Y., Ting L.T., Chiang H.: Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma. Cancer 2002; 94: 1538-1547.
  • 106. Moradi A., Semnani V., Djam H. i wsp.: Pathodiagnostic parameters for meningioma grading. J. Clin. Neurosci. 2008; 15: 1370-1375.
  • 107. de la Monte S.M., Flickinger J., Linggood R.M.: Histopathologic features predicting recurrence of meningiomas following subtotal resection. Am. J. Surg. Pathol. 1986; 10: 836-843.
  • 108. McLean C.A., Jolley D., Cukier E. i wsp.: Atypical and malignant meningiomas: importance of micronecrosis as a prognostic indicator. Histopathology. 1993; 23: 349-353.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-a7bffedd-a970-4ff3-a354-92b05d825cb3
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.